statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb PR Newswire VANCOUVER, BC, May 9, 2024 USA...

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Janux Therapeutics Options Trading: A Deep Dive into Market Sentiment

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday.
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday's session.
read more...

Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday

Investors eyeing a purchase of Janux Therapeutics Inc (JANX) shares, but tentative about paying the going market price of 35.70/share, might benefit from considering selling puts among the...

Commit To Purchase Janux Therapeutics At $25, Earn 26.5% Annualized Using Options

Investors might want to bet on Janux Therapeutics, Inc. (JANX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which...

Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX  Get Free Report) have been assigned a consensus rating of Buy from the six analysts that are covering the firm, MarketBeat...

Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $59.60

Cantor Fitzgerald assumed coverage on shares of Janux Therapeutics (NASDAQ:JANX  Free Report) in a research report sent to investors on Wednesday, MarketBeat reports. The firm issued an...

Cantor Fitzgerald Begins Coverage on Janux Therapeutics (NASDAQ:JANX)

Investment analysts at BTIG Research started coverage on shares of Janux Therapeutics (NASDAQ:JANX  Get Free Report) in a research report issued on Thursday, Marketbeat reports. The brokerage...

BTIG Research Initiates Coverage on Janux Therapeutics (NASDAQ:JANX)

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.

Watchers	654
52-Wk Low	$5.65
52-Wk High	$65.60

Volume	427,765.00
52-Wk High	$65.60
52-Wk Low	$5.65

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.31	--	--	N/A
Q1'24	-$0.33	-$0.30	9.43%	BEAT
Q4'23	-$0.42	-$0.25	39.79%	BEAT
Q3'23	-$0.47	-$0.25	46.81%	BEAT
Q2'23	-$0.50	-$0.42	16.33%	BEAT

JANX Janux Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals